Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Atopic Dermatitis

NCT05466877 is registered in ClinicalTrials.gov with Shanghai Mabgeek Biotech.Co.Ltd as lead sponsor.

NCT NCT05466877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05466877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Atopic Dermatitis
Lead sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2022
Completion date
May 26, 2024
Enrollment
163 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis